NCT02788032

Brief Summary

This open-label, prospective, controlled intervention study involves evaluating tolerance and acceptability of an Oral Nutrition Supplement (ONS; EnergieShake®) in 16 adult patients who are already taking an ONS. Following a 2-day baseline data collection on their current ONS, patients switch to the test ONS, which is taken for a further 8 consecutive days. Patients revert to their current ONS at the end of the study. Patients act as their own controls and thus all patients are allocated the same intervention. Daily records of GI tolerance and compliance with the prescribed amount of ONS will be kept for participants throughout the study period. Participants' height and weight will be collected at baseline (weight at end will also be collected), all medications will be documented, and relevant medical and dietary histories will be recorded. A questionnaire at the end of the intervention period will be administered collecting participants' views on the acceptability (taste and palatability) of the test ONS. Taste and palatability will be assessed via a questionnaire that uses a Hedonic scale to quantify preference.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
18

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2016

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 24, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 2, 2016

Completed
29 days until next milestone

Study Start

First participant enrolled

July 1, 2016

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

June 2, 2016

Status Verified

May 1, 2016

Enrollment Period

Same day

First QC Date

May 24, 2016

Last Update Submit

June 1, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Tolerance: how well the participant tolerates the Oral Nutritional Supplement, including changes to gastrointestinal symptoms.

    The primary objective of the study is to assess gastrointestinal (GI) tolerance (bowel frequency and consistency using the Bristol Stool Chart, nausea, vomiting, abdominal discomfort, wind, burping, flatulence) to test Oral Nutrition Supplement (EnergieShake®, a powdered nutritional supplement, classified as a Food for Special Medical Purposes for the dietary management of disease-related malnutrition) in patients requiring ONS.

    10 days

Secondary Outcomes (1)

  • How acceptable the Oral Nutritional Supplement is to the participant, (taste, texture, aroma, consistency, etc.) Compliance with Oral Nutritional Supplement.

    10 days

Study Arms (1)

EnergieShake Intervention

OTHER

Single arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.

Other: EnergieShake oral supplement

Interventions

The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®

EnergieShake Intervention

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (18 years or older)
  • Participants with or at risk of malnutrition who are already taking ONS on a daily basis
  • Participants expected to continue to require ONS for at least a further 2 weeks
  • Participants able to give their informed consent to participate

You may not qualify if:

  • Requirement of tube or parenteral nutrition.
  • Participants receiving palliative care.
  • Participants with chronic renal disease or liver failure.
  • Participants requiring a milk/lactose free diet
  • Participants with significant on-going gastrointestinal symptoms.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fermoyle Nursing Home

London, Surrey, KT15 1SH, United Kingdom

Location

MeSH Terms

Conditions

Malnutrition

Condition Hierarchy (Ancestors)

Nutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Ryan Rodrigues, Masters

    Anaiah Healthcare Ltd

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Joyce Sibiya

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2016

First Posted

June 2, 2016

Study Start

July 1, 2016

Primary Completion

July 1, 2016

Study Completion

July 1, 2016

Last Updated

June 2, 2016

Record last verified: 2016-05

Data Sharing

IPD Sharing
Will not share

Locations